Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases

The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non‐oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non‐oncological diseases and (b) the risk–benefit ratio of treating p...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Pharmacol
Autori principali: Berger, Nathan A, Besson, Valerie C, Boulares, A Hamid, Bürkle, Alexander, Chiarugi, Alberto, Clark, Robert S, Curtin, Nicola J, Cuzzocrea, Salvatore, Dawson, Ted M, Dawson, Valina L, Haskó, György, Liaudet, Lucas, Moroni, Flavio, Pacher, Pál, Radermacher, Peter, Salzman, Andrew L, Snyder, Solomon H, Soriano, Francisco Garcia, Strosznajder, Robert P, Sümegi, Balázs, Swanson, Raymond A, Szabo, Csaba
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Themed Section: Review Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5758399/
https://ncbi.nlm.nih.gov/pubmed/28213892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13748
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi